Alpha MSH in Ocular Disease

Completed · Not applicable

Conditions studied: Advanced Dry Macular Degeneration

In brief

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Key facts

Study ID

NCT03451578

Run by

Duke University

People needed

54

Starts

2018-03-06

Expected to finish

2021-10-19

Last updated by the study team

2022-12-22

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 60 years or older
• diagnosis of advanced dry macular degeneration with foveal geographic atrophy
• limited vision or blindness (20/100 or worse) in that eye
• pseudophakia (prior cataract surgery in that eye)

Where it is running

• Duke University Eye Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.